Richard H Stanford1,2, Stephanie Korrer3, Lee Brekke3, Tyler Reinsch1, Lindsay G S Bengtson3. 1. Strategic Consulting, AESARA, Inc., Chapel Hill, North Carolina. 2. Department of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill. 3. Health Economics and Outcomes Research, Optum Inc., Eden Prairie, Minnesota.
Abstract
BACKGROUND: Population-based risk assessments are needed to identify individuals who may benefit from chronic obstructive pulmonary disease (COPD) management programs for preventing exacerbations. This study compared the validated COPD treatment ratio (CTR) versus other COPD exacerbation predictors: prior exacerbation and rescue and maintenance medication use. METHODS: A retrospective observational study using medical and pharmacy claims data among Medicare Advantage with Part D beneficiaries with COPD (January 2011-August 2016). Unadjusted and adjusted logistic regression models tested the predictive performance (C-statistic) of potential exacerbation predictors for future severe exacerbations. RESULTS: The unadjusted association between exacerbation predictors and severe exacerbation was examined in 60,776 patients: baseline severe exacerbation had the highest C-statistic (0.668), then number of rescue units dispensed (0.651), CTR (0.619), and number of controller units dispensed (0.562). During the at-risk period, baseline CTR was inversely associated with severe exacerbation (odds ratio, <1.0); other predictors were positively associated with a severe exacerbation (odds ratio, >1.0). Adjusting for age, geographic region, chronic oxygen, and nebulizer use, the severe exacerbation odds were 0.90 (95% confidence interval [CI], 0.89-0.91) lower per 0.10 change in CTR (C-statistic, 0.710). The C-statistic was 0.734 when baseline exacerbation was added to the model. CONCLUSIONS: The CTR is an effective tool for identifying patients diagnosed with COPD who are at increased risk of severe exacerbation. Although CTR does not predict future exacerbation as well as prior severe exacerbation history, it has the advantage of being applicable in predicting future exacerbations in patients without an exacerbation history, or in databases limited to pharmacy claims only. In addition, the significant reduction in risk has been observed with incremental increases in the ratio: the ratio can be monitored to assess COPD health improvements over time. JCOPDF
BACKGROUND: Population-based risk assessments are needed to identify individuals who may benefit from chronic obstructive pulmonary disease (COPD) management programs for preventing exacerbations. This study compared the validated COPD treatment ratio (CTR) versus other COPD exacerbation predictors: prior exacerbation and rescue and maintenance medication use. METHODS: A retrospective observational study using medical and pharmacy claims data among Medicare Advantage with Part D beneficiaries with COPD (January 2011-August 2016). Unadjusted and adjusted logistic regression models tested the predictive performance (C-statistic) of potential exacerbation predictors for future severe exacerbations. RESULTS: The unadjusted association between exacerbation predictors and severe exacerbation was examined in 60,776 patients: baseline severe exacerbation had the highest C-statistic (0.668), then number of rescue units dispensed (0.651), CTR (0.619), and number of controller units dispensed (0.562). During the at-risk period, baseline CTR was inversely associated with severe exacerbation (odds ratio, <1.0); other predictors were positively associated with a severe exacerbation (odds ratio, >1.0). Adjusting for age, geographic region, chronic oxygen, and nebulizer use, the severe exacerbation odds were 0.90 (95% confidence interval [CI], 0.89-0.91) lower per 0.10 change in CTR (C-statistic, 0.710). The C-statistic was 0.734 when baseline exacerbation was added to the model. CONCLUSIONS: The CTR is an effective tool for identifying patients diagnosed with COPD who are at increased risk of severe exacerbation. Although CTR does not predict future exacerbation as well as prior severe exacerbation history, it has the advantage of being applicable in predicting future exacerbations in patients without an exacerbation history, or in databases limited to pharmacy claims only. In addition, the significant reduction in risk has been observed with incremental increases in the ratio: the ratio can be monitored to assess COPD health improvements over time. JCOPDF
Authors: Eva Balcells; Josep M Antó; Joaquim Gea; Federico P Gómez; Esther Rodríguez; Alicia Marin; Antoni Ferrer; Jordi de Batlle; Eva Farrero; Marta Benet; Mauricio Orozco-Levi; Jaume Ferrer; Alvar G Agustí; Juan B Gáldiz; José Belda; Judith Garcia-Aymerich Journal: Respir Med Date: 2009-05-08 Impact factor: 3.415
Authors: Dennis E Niewoehner; Yuliya Lokhnygina; Kathryn Rice; Ware G Kuschner; Amir Sharafkhaneh; George A Sarosi; Peter Krumpe; Karen Pieper; Steven Kesten Journal: Chest Date: 2007-01 Impact factor: 9.410
Authors: John R Hurst; Jørgen Vestbo; Antonio Anzueto; Nicholas Locantore; Hana Müllerova; Ruth Tal-Singer; Bruce Miller; David A Lomas; Alvar Agusti; William Macnee; Peter Calverley; Stephen Rennard; Emiel F M Wouters; Jadwiga A Wedzicha Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: Janet B Croft; Anne G Wheaton; Yong Liu; Fang Xu; Hua Lu; Kevin A Matthews; Timothy J Cunningham; Yan Wang; James B Holt Journal: MMWR Morb Mortal Wkly Rep Date: 2018-02-23 Impact factor: 17.586
Authors: Wilhelmine H Meeraus; Hana Mullerova; Céline El Baou; Marion Fahey; Edith M Hessel; William A Fahy Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-02-05